Global Artemisinin Market Size study, by Malaria Type (Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Malariae, Plasmodium Knowlesi), Product (Injections, Tablets), Type (Combination, Monotherapy) and Regional Forecasts 2022-2032

Global Artemisinin Market is valued approximately at USD 0.67 billion in 2023 and is anticipated to grow with a steady CAGR of more than 4.2% over the forecast period 2024-2032. Artemisinin, a naturally derived antimalarial compound sourced from the Artemisia annua plant, has emerged as the cornerstone of modern malaria therapy. Its potent efficacy, particularly against drug-resistant strains of Plasmodium falciparum, has led to widespread adoption across both monotherapy and combination treatments. As malaria continues to pose a major health burden, especially across tropical and subtropical regions, the strategic role of artemisinin-based therapies remains paramount in global health initiatives aiming to curb and eliminate the disease.

The market's momentum is being accelerated by growing malaria prevalence in sub-Saharan Africa and parts of Southeast Asia, prompting increased government procurement of artemisinin-based combination therapies (ACTs). With international agencies like WHO and Global Fund supporting subsidized treatment access and stockpile reserves, the commercial production of artemisinin and its derivatives has scaled substantially. Meanwhile, pharmaceutical manufacturers are developing novel formulations-such as artemisinin-piperaquine fixed-dose combinations and long-acting injectables-to enhance compliance and therapeutic impact. Further, growing awareness of plant-based APIs and integrated vector control programs are expected to complement the demand trajectory through 2032.

Nevertheless, challenges persist that could restrain the market from achieving its full potential. The volatility in artemisinin raw material pricing-due to weather-dependent cultivation-poses a supply chain risk. Additionally, emerging resistance to ACTs in parts of Southeast Asia and Oceania threatens to undermine treatment efficacy, urging a need for next-gen derivatives and resistance-monitoring systems. Furthermore, limited production infrastructure in low-income countries and quality compliance issues remain areas that necessitate regulatory and logistical interventions. However, biotechnological breakthroughs in semi-synthetic artemisinin synthesis and expanding research into artemisinin-based cancer and anti-inflammatory therapies offer promising avenues for diversification and market expansion.

Technological advancements are redefining artemisinin manufacturing through synthetic biology approaches and fermentation-based methods, which aim to stabilize supply chains and reduce ecological dependency. Simultaneously, the growing trend of public-private partnerships, especially between global health bodies and pharma producers, is fostering innovation and ensuring equitable access. The rise of e-pharmacies and digitized distribution networks has further strengthened last-mile delivery of malaria treatments in remote areas, paving the way for enhanced market penetration and real-time stock monitoring.

Regionally, the Asia Pacific market dominates the artemisinin industry, led by high malaria-endemic zones and a strong production base in China and Vietnam. Africa follows closely, driven by large-scale donor-funded healthcare campaigns and a rising commitment from national health ministries. Latin America is showing a steady uptake, supported by WHO's malaria elimination roadmap in the region. Meanwhile, North America and Europe, though low in malaria burden, are contributing to the market via research grants, vaccine integration trials, and export of pharmaceutical-grade artemisinin derivatives.

Major market player included in this report are:

• Guilin Pharmaceutical Co., Ltd.
• Sanofi S.A.
• Novartis AG
• Cipla Limited
• IPCA Laboratories Ltd.
• Zhenhua Pharma Co., Ltd.
• Artecef B.V.
• KPC Pharmaceuticals, Inc.
• Calyx Chemicals and Pharmaceuticals Ltd.
• Shanghai Natural Bio-engineering Co., Ltd.
• Zhifei Biological Products Co., Ltd.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Zhejiang Holley Pharmaceutical Co., Ltd.
• Guangdong New South Group Co., Ltd.
• Ajanta Pharma Ltd.

The detailed segments and sub-segment of the market are explained below:

By Malaria Type

• Plasmodium Falciparum
• Plasmodium Vivax
• Plasmodium Ovale
• Plasmodium Malariae
• Plasmodium Knowlesi

By Product

• Injections
• Tablets

By Type

• Combination
• Monotherapy

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with country-level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.